The growing existence of non-alcoholic steatohepatitis is driving market growth.
New York, USA, Dec. 16, 2024 (GLOBE NEWSWIRE) — Market Statistics
The global non-alcoholic steatohepatitis treatment market size was USD 7.70 billion in 2024, estimated at USD 9.85 billion in 2025, and is expected to reach around USD 90.97 billion by 2034, expanding at a CAGR of 28.0% from 2025 to 2034.
What is Non-Alcoholic Steatohepatitis Treatment?
The premiere line of treatment for NAFLD and NASH is weight loss, executed through a merger of calorie decrease, exercise, and wholesome consumption. Weight loss can reduce fat and inflammation in the liver. Mislaying just 3 to 5 percent of body weight can decrease fat in the liver, and mislaying 7 percent can reduce inflammation as well. If one is overweight and obese, doctors normally suggest one moderately lose 7 to 10 percent of body weight over a period of one year. Speedy weight loss through fasting is not endorsed as it can make NAFLD worse.
Download Free Sample PDF Copy of Report:
Key Takeaways from Report
- The market is expected to exhibit at a CAGR of 28.0%.
- The market for non-alcoholic steatohepatitis treatment is expanding due to the growing escalation in the existence of obesity.
- The non-alcoholic steatohepatitis treatment market analysis is primarily based on drug, disease stage, distribution channel, and region.
- Based on the drug, the vitamin E and pioglitazone segment dominated the market.
- North America dominated the market with the largest share and is anticipated to continue its dominance during the forecast period.
Non-Alcoholic Steatohepatitis Treatment Market Dynamics
Growth Drivers
Growing Aging Population: The non-alcoholic steatohepatitis treatment market is expanding due to the growing aging population globally, increasing the cases of NASH-connected liver illness with older adults at elevated probability for situations such as diabetes and hypertension connected to NASH. As per the World Health Organization, from 2015 to 2050, the percentage of the worldwide population aged 60 and above is expected to roughly double from 12% to 22%, underscoring crucial insinuations for social, economic, and healthcare sectors.
Growing Existence of Type 2 Diabetes: Insulin aversion, a normal attribute in diabetes, causes fat increase in the liver, establishing the phase for liver soreness and fibrosis linked with NASH. The International Diabetes Federation registered that 537 million persons were suffering from diabetes globally in 2021. Estimates expect the aggregate will surge to 643 million by 2030 and 783 million by 2045, underscoring a pressing requirement for productive public health schemes.
Trends and Opportunities
Growing Funding by Governments: Governments and health firms are boosting endeavors to confront liver illnesses involving NASH through public health crusades, research funding, and improved eruption for diagnostic instruments. This concentration is pushing greater identification of NASH as a notable and growing health worry, suggesting that the non-alcoholic steatohepatitis treatment market is expanding.
Progressions in Diagnostic Methodologies: Progressions in diagnostic methodologies are improving the premature noticing of NASH a crucial element for productive cure. The advancement of noninvasive instruments such as elastography and biomarkers has enhanced diagnostic preciseness, pushing the demand for the market.
Request for Discount on this Report Before Purchase:
Competitive Analysis
The aggressive topography of the market is portrayed by a zestful and developing ambiance, with many critical contenders spearheading the path of drug advancement and treatment invention. Spearheading pharmaceutical firms involving Intercept Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, and Novo Nordisk, are at the vanguard of diligently included in clinical trials and instigating therapies.
Major players operating in non-alcoholic steatohepatitis treatment market are:
- Intercept Pharmaceuticals, Inc.
- Galmed Pharmaceuticals Ltd
- Inventiva
- AbbVie Inc.
- Galectin Therapeutics Inc.
- Madrigal Pharmaceuticals Inc (Madrigal)
- NGM Biopharmaceuticals, Inc.
- Novo Nordisk A/S
- The Bristol-Myers Squibb Company
- Gilead Sciences, Inc.
Regional Insights
North America: The region held the largest market share due to the elevated existence of probability elements such as obesity, type 2 diabetes, and metabolic syndrome, which are prominent donors to the surge in NASH cases.
Asia Pacific: The growing consciousness of NASH and its difficulties, together with enhanced healthcare framework and augmenting admission to progressive treatment alternatives, are expected to drive the Asia Pacific non-alcoholic steatohepatitis treatment market with the highest CAGR during the forecast period.
Inquire more about this report before purchasing:
Non-alcoholic Steatohepatitis Treatment Market Segmentation
By Drug Outlook
- Vitamin E and Pioglitazone
- Obeticholic Acid (OCA)
- Lanifibranor
- Semaglutide
- Resmetirom
- Aramchol
- Cenicriviroc
- Other Drugs
By Disease Stage Outlook
- NASH Stage F0
- NASH Stage F1
- NASH Stage F2
- NASH Stage F3
- NASH Stage F4
By Distribution Channel Outlook
- Hospital Pharmacies
- Retail and Specialty Pharmacies
- Other Pharmacies
By Regional Outlook
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of the Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
More Trending Latest Reports by Polaris Market Research:
Teleradiology Software Market Growth
Breast Cancer Liquid Biopsy Marke
Digital X-Ray Market Opportunities
Drug Device Combination Products Market Trends
About Polaris Market Research & Consulting, Inc:
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR’s clientele spread across different enterprises. We at Polaris are obliged to serve PMR’s diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR’s customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR’s customers.
Contact:
Likhil G
8 The Green Ste 19824,
Dover, DE 19901,
United States
Phone: +1-929 297-9727
Email: sales@polarismarketresearch.com
Web: https://www.polarismarketresearch.com
- New Smyrna Beach Tree Service Earns Perfect 5-Star Rating from Satisfied Customers - July 2, 2025
- Cut Rite Tree Service Fresno Expands Operations to Visalia and Tulare, Adding Additional Crews to Meet Growing Demand - July 2, 2025
- New Horizon Tree Service Awarded Major Government Contract for Municipal Tree Care in Goodlettsville - July 2, 2025
